
Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, openlabel safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy

Bonus Makanani, MBBS, FCOG(SA)¹, Lee Fairlie, MBChB, FCPaeds², Jennifer E. Balkus PhD^{3,4}, MPH, Daniel Szydlo, MS⁴, Nyaradzo M. Mgodi, MBChB, MMed⁵, Clemensia Nakabiito, MBChB, MMed⁶, Ashley J. Mayo, MSPH⁷, Jeanna M. Piper, MD⁸, Nahida Chakhtoura, MD, MsGH⁹, Sharon L. Hillier, PhD¹⁰, Katherine Bunge, MD, MPH¹⁰, for the MTN-042/DELIVER Team.

¹Malawi College of Medicine-Johns Hopkins University Research Project; ²Wits Reproductive Health and HIV Institute, University of the Witwatersrand; ³Department of Epidemiology, University of Washington School of Public Health; ⁴Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center; ⁵University of Zimbabwe Clinical Trials Research Centre (UZ-CTRC) ⁶Makerere University - John's Hopkins University (MU-JHU) Research Collaboration; ⁷FHI 360; ⁸National Institute of Allergy and Infectious Diseases, National Institutes of Health; ⁹Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; ¹⁰Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh

Background


- The monthly dapivirine vaginal ring (DVR) has been clinically shown to reduce HIV risk with a favorable safety profile in non-pregnant reproductive-aged women^{1,2}
- The WHO recently recommend DVR for use among women at increased risk of HIV acquisition;³ however, safety data on use during pregnancy are lacking
- Here we report interim safety data from the first cohort of pregnant participants in MTN-042/DELIVER, a phase IIIb, randomized, open-label safety trial of DVR and oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (ClinicalTrials.gov number: NCT03965923)



Methods

- Eligible women aged 18 to 40 in Blantyre, Malawi; Johannesburg, South Africa; Kampala, Uganda and Chitungwiza, Zimbabwe were randomized 2:1 to monthly DVR or daily TDF/FTC
- Participants initiated product use between 36 0/7-37 6/7 weeks' gestation and continued until delivery or 41 6/7 weeks gestation
- Pregnancy outcomes and complications reported at the time of delivery were assessed and summarized using descriptive statistics and compared to local background rates obtained through a chart review (MTN-042B)⁴

In this first study of a long-acting HIV prevention agent used in pregnancy, adverse pregnancy outcomes and complications were uncommon when the dapivirine vaginal ring and tenofovir disoproxil fumarate/emtricitabine were used in late pregnancy and were generally similar to rates observed in the communities where the study is being conducted.



Enrolled	101 Dapivirine vaginal ring		49 TDF/FTC			'n	eivirine =99	ľ	F/FTC 1=49		Over N=1/	48	
_					Stillbirth		(%) (0)		1 (2)		N (9 1 (-	
Pregnancy outcome available*	99 Dapivirine		49 TDF/FTC		Live birth	99	(100)	4	8 (98)	1	47 ((99)	
	vaginal ring				Full term birth	98	(99)	4	6 (96)	1	44 ((98)	
	participant was lost to follow-up following their Week 1 Phone Contact visit' 1				Preterm birth	1	(1)		2 (4)		3 ((2)	

participant withdrew consent after randomization but prior to study product administration

Table 2. Maternal pregnancy complications by study arm¹

	Dapivirine n=99 n (%)	TDF/FTC n=49 n (%)	MTN-042B frequencies ² % (95% CI)
Any hypertensive disorder of pregnancy ³	3 (3)	4 (8)	10.6% (10.0, 11.3)
Gestational hypertension	3 (3)	2 (4)	4.4% (4.0, 4.8)
Pre-eclampsia without severe features	0 (0)	1 (2)	2.2% (1.9, 2.5)
Pre-eclampsia with severe features	0 (0)	1 (2)	2.1% (1.9, 2.4)
Eclampsia	0 (0)	0 (0)	0.6% (0.5, 0.8)
Hemorrhage			
Peripartum/Antepartum hemorrhage	0 (0)	1 (2)	
Postpartum hemorrhage	2 (2)	1 (2)	3.2% (2.9, 3.6)


¹Other complications assessed included: chorioamnionitis, puerperal sepsis, endometritis, preterm premature rupture of membranes, and fever of unclear etiology.

²Data on background rates obtained as part of a published systematic chart review (MTN-042B).

³Participants may experience more than one form of hypertensive disorder in pregnancy, therefore the sum of the rows may be higher than the total number of participants in this row.

Conclusions

- In this first study of a long-acting HIV prevention agent in pregnancy, adverse pregnancy outcomes and complications were uncommon when the DVR and TDF/FTC were used in late pregnancy and were generally similar to rates observed in the communities where the study is being conducted
- These data support plans for subsequent investigation of safety among pregnant women using DVR earlier in pregnancy



Pregnancy complications were rare, with hypertensive disorders being the most common complication reported (Table 2)

Severe Adverse Events (SAEs)

Maternal SAEs • Of the SAEs/grade \geq 3 AEs reported, only one AE (grade III nausea) was deemed related to study product use in the **TDF/FTC** arm

Infant SAEs

- There were no infant SAEs/grade ≥3 AEs related to study product
- At the time of this report, there was one neonatal death following delivery in the TDF/FTC arm

References

1. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med 2016;375:2121-32. 2.Nel A, van Niekerk N, Kapiga S, et al. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. N Engl J Med 2016;375:2133-43. 3. WHO. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. 26 January 2021 4.Balkus JE, Neradilek M, Fairlie L, et al. Assessing pregnancy and neonatal outcomes in

Malawi, South Africa, Uganda, and Zimbabwe: Results from a systematic chart review. PLoS One 2021;16:e0248423.



We are immensely grateful to the pregnant individuals and their infants who are participating in the DELIVER study.

The Microbicide Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The vaginal rings used in this study were developed and supplied by the International Partnership for Microbicides (IPM). Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) was donated by Gilead Sciences.

